New Drug & Incrementally Modified Drugs
| Classification | Project | Indication | Formulation research |
phase 1 | phase 2 | phase 3 | Others | |
|---|---|---|---|---|---|---|---|---|
FDC |
DKB15003 |
Dyslipidemia |
|
NDA |
||||
DKB17001 |
BPH/OAB |
|
||||||
DKB17002 |
Lumbago |
|
||||||
DKB19001 |
Hypertension/ Hyperlipidemia |
|
On market |
|||||
DKB19002 |
Diabetes |
|
NDA |
|||||
DKB19003 |
Allergic rhinitis |
|
||||||
Others |
DKB20003 |
Venous Lymphatic insufficiency |
|
|||||
| IMD | Sustained release |
DKB20001 |
Diabetes |
|
||||
DKB20002 |
Diabetes |
|
||||||
DKB20004 |
Diabetes |
|
||||||
| New drugs | NCP112 |
Atopic dermatitis |
|
Joint development project (in charge of formulation development) |
||||
Open Innovation |
Joint development plans for new drugs for shingles, degenerative brain disease, etc.
|
|||||||
Differentiated medicines
| Project | Subject | Indication | Formulation research | Bioequivalence / Clinical phase 1 | Others |
|---|---|---|---|---|---|
| New Salt | DKB1904 |
Allergy/dermatitis |
|
||
| First introduction in Korea |
DKB1801 |
Acne |
|
Low dose introduction |
|
DKB1902 |
Psoriasis |
|
Mid-dose introduction |
||
| Preferential marketing license |
DKB1903 |
Diabetes |
|
||
DKB1903C |
Diabetes |
|
|||
DKB2001 |
Diabetes |
|
|||
DKB2014 |
Psoriasis |
|
|||
License in
| Item | Contract description | District | Contract Date | Development status |
|---|---|---|---|---|
Cernilton Tab |
API exclusive supply and distribution/sales contract |
South Korea, Taiwan, Mongolia, ASEAN, GCC |
17.01 |
On market |
Cernitol Novum |
Exclusive distribution/sales contract |
South Korea, Taiwan, Mongolia, ASEAN, GCC |
18.03 |
Ready for KFDA submission |
MOB-015 |
Exclusive distribution/sales contract |
South Korea |
19.10 |
Phase 3 |